- Home
- GRCE vs ADVM Comparison
GRCE vs ADVM Comparison
Compare GRCE & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRCE
- ADVM
- Stock Information
- Founded
- GRCE 2002
- ADVM 2006
- Country
- GRCE United States
- ADVM United States
- Employees
- GRCE N/A
- ADVM N/A
- Industry
- GRCE
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRCE
- ADVM Health Care
- Exchange
- GRCE NYSE
- ADVM Nasdaq
- Market Cap
- GRCE 42.4M
- ADVM 47.4M
- IPO Year
- GRCE N/A
- ADVM 2014
- Fundamental
- Price
- GRCE $3.08
- ADVM $2.70
- Analyst Decision
- GRCE Strong Buy
- ADVM Strong Buy
- Analyst Count
- GRCE 1
- ADVM 5
- Target Price
- GRCE $12.00
- ADVM $23.80
- AVG Volume (30 Days)
- GRCE 62.2K
- ADVM 277.9K
- Earning Date
- GRCE 08-15-2025
- ADVM 08-11-2025
- Dividend Yield
- GRCE N/A
- ADVM N/A
- EPS Growth
- GRCE N/A
- ADVM N/A
- EPS
- GRCE N/A
- ADVM N/A
- Revenue
- GRCE N/A
- ADVM $1,000,000.00
- Revenue This Year
- GRCE N/A
- ADVM N/A
- Revenue Next Year
- GRCE N/A
- ADVM $18.82
- P/E Ratio
- GRCE N/A
- ADVM N/A
- Revenue Growth
- GRCE N/A
- ADVM N/A
- 52 Week Low
- GRCE $1.75
- ADVM $1.78
- 52 Week High
- GRCE $4.97
- ADVM $8.58
- Technical
- Relative Strength Index (RSI)
- GRCE N/A
- ADVM 54.36
- Support Level
- GRCE N/A
- ADVM $2.57
- Resistance Level
- GRCE N/A
- ADVM $2.85
- Average True Range (ATR)
- GRCE 0.00
- ADVM 0.21
- MACD
- GRCE 0.00
- ADVM 0.02
- Stochastic Oscillator
- GRCE 0.00
- ADVM 62.42
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.